PPBT Stock Catalyst: Purple Biotech Presented New Cancer Immunotherapy Data at EACR 2026

Jun 11, 2026 · 7:02am ET

Company stated that IM1240 data support the first human study in 2027.

Max move

+102.0%

High of day $5.98

Sparker timei

7:02am ET

PPBT · Jun 11, 2026

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Purple Biotech Ltd. (Nasdaq: PPBT) presented new data on its cancer immunotherapy at the European Association for Cancer Research (EACR) 2026 conference. The company announced that the data from its IM1240 program support the initiation of the first human study in 2027.

No financial amounts or filings were reported in connection with this announcement. The company's free float stands at 130,524 shares.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time PPBT sparks.

Download Sniper App →

Catch the next PPBT-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →